Li et al. have conducted an experimental study in which they have linked trastuzumab with a α-amanitin, a specific inhibitor of POLR2A. This combination (called T-Ama) has shown a higher efficacy in treating patients who had a 17p-mutated HER2-low BC [48]. The gene discussed is ERBB2; the disease is breast cancer.